UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2015

LANTHEUS MEDICAL IMAGING, INC.
(Exact name of registrant as specified in its charter)

 
 	 	 	 	 	
Delaware	 	333-169785	 	51-0396366	
(State or other jurisdiction
of incorporation)	 	(Commission
File Number)	 	(IRS Employer
Identification No.)	
331 Treble Cove Road, North Billerica, MA 01862
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (978) 671-8001
Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

 
 
Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers	
Appointment of New Chief Operating Officer
On March 16, 2015, Lantheus Medical Imaging, Inc. (the “Company”) announced its promotion of Mary Anne Heino to the position of Chief Operating Officer. Ms. Heino, age 55, had previously served as the Company’s Chief Commercial Officer, a position she held since joining the Company in April 2013.
Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson Company, including Vice President Strategic Planning and Competitive Intelligence, Vice President Sales, Executive Director Customer Relationship Management and Senior Director Immunology Marketing. Ms. Heino began her professional career with Janssen Pharmaceutica as a Sales Representative in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master’s in Business Administration from New York University. She earned a Bachelor’s of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook.
In connection with Ms. Heino’s new position as Chief Operating Officer, her base salary payable under her existing employment agreement was increased to $400,000, effective as of March 16, 2015, and the target amount of her annual bonus award under her existing employment agreement was increased to 60% of her new base salary. The terms of her existing employment agreement are incorporated herein by reference from Item 11 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Such terms are a summary only and qualified in their entirety by reference to the full text of Ms. Heino’s Employment Agreement, attached as an exhibit thereto and incorporated by reference herein.
A copy of the Company’s press release, dated March 16, 2015, announcing the promotion of Ms. Heino to Chief Operating Officer is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01.	Financial Statements and Exhibits.	
(d) Exhibits

Exhibit
No.	  	Description	
 	 	
99.1	  	Press release of Lantheus Medical Imaging, Inc. dated March 16, 2015, announcing the promotion of Mary Anne Heino to Chief Operating Officer.	

 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS MEDICAL IMAGING, INC.	
 	 	
By:	 	/s/ Michael P. Duffy	
Name:
Title:	 	Michael P. Duffy
Vice President and General Counsel	
Date: March 16, 2015

 
EXHIBIT INDEX

Exhibit
No.	  	Description	
 	 	
99.1	  	Press release of Lantheus Medical Imaging, Inc. dated March 16, 2015, announcing the promotion of Mary Anne Heino to Chief Operating Officer.	

Exhibit 99.1

FOR IMMEDIATE RELEASE
CONTACTS:
Meara Murphy
978-671-8508
Linda Lennox
978-671-8854
LANTHEUS MEDICAL IMAGING PROMOTES
MARY ANNE HEINO TO CHIEF OPERATING OFFICER
No. BILLERICA, Mass. (March 16, 2015) – Lantheus Medical Imaging, Inc. (“Lantheus” or “the Company”), a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today announced the promotion of Mary Anne Heino to Chief Operating Officer (COO), a newly created position in the Company, effective March 16, 2015. Ms. Heino, who has served as Chief Commercial Officer since April 2013, will continue to report to Jeff Bailey, Lantheus’ President and Chief Executive Officer.
As COO, Ms. Heino will oversee the daily management of all the operations that manufacture, sell and distribute the Company’s products. In addition to her current responsibilities leading the Company’s Commercial and International operations, Ms. Heino will assume leadership for Manufacturing and Operations, and will be responsible for the integration with Quality and Regulatory Affairs.
“I am very pleased to announce Mary Anne’s appointment to the new role of Chief Operating Officer,” said Mr. Bailey. “She brings proven leadership and expertise in all facets of pharmaceutical operations to this important role. With her success leading our overall commercial strategy and driving strong results for our Global Sales & Marketing organization, she is ideally suited to ensure alignment across Commercial, Manufacturing & Operations, Quality and Regulatory Affairs, allowing us to continue to advance the transformation of our operations and provide for the long-term success of the Company.”
“It’s an honor to take on this new challenge at Lantheus, and I am looking forward to further strengthening and building upon the Company’s commercial and operational success that has occurred over the past two years,” said Ms. Heino. “Integrating the Commercial and Manufacturing & Operations teams is essential to ensuring that our trusted brands are always available to the medical community so that they can better manage care of their patients.”

With more than 25 years of demonstrated pharmaceutical and biotech industry experience, Ms. Heino is well positioned to lead the Company’s operations. Prior to joining Lantheus in 2013, Ms. Heino was the President of Angelini Labopharm, an international pharmaceutical joint venture, with responsibility for Commercial, Manufacturing, Quality, Regulatory Affairs and other functions, as well as was instrumental in setting up the company’s supply chain. Additionally, Ms. Heino gained progressive executive experience with Centocor, Inc. and Janssen Pharmaceutica during her 18-year tenure with the Johnson & Johnson Family of Companies. While at Centocor, she led both the Cardiovascular and Immunology sales forces, as well as key areas of Commercial Operations. Ms. Heino received a B.S. in Nursing from the City University of New York, a B.S. in Biology from Stony Brook University, and an M.B.A. from The Stern School of Business at New York University.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents. The Company provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. Lantheus’ key products include the echocardiography contrast agent DEFINITY ®  Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite ®  (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon Xe 133 Gas (Xenon 133), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.
Lantheus has more than 500 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit  www.lantheus.com .
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
# # #